A study involving 743 psoriasis patients compared the efficacy and safety of bimekizumab versus secukinumab over three years. All participants transitioned to bimekizumab for long-term assessment. At the three-year mark, PASI 100 response rates were 68.8% for both bimekizumab and secukinumab switchers, while PASI 90 was achieved in 89.7% of continuous bimekizumab users. The treatment demonstrated a favorable safety profile with manageable adverse events, affirming bimekizumab's effectiveness in managing moderate-to-severe psoriasis.

Source: BJD